The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.
An innovative diagnostic medical device company striving to aid ophthalmologists in the fight against ocular hypertension and glaucoma induced blindness by providing continuous intraocular pressure fluctuation data for 24 hours.
Istanbul, Istanbul, Turkey
Send a message
GlakoLens scored 13.8/15 (ESR) in its first SME Instrument Phase 2 (EIC Accelerator) submission receiving its third Seal of Excellence Award from the European Commission with the project titled, SaveSight2: Contact Lens Embedded Sensor for Ocular Hypertension and Glaucoma Monitoring. The Seal of Excellence was awarded for the last cut-off of the EIC Accelerator program within the Horizon 2020 Framework, the most competitive round so far with more than 1700 submissions.
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded in a highly competitive evaluation process by independent experts but did not receive funding due to budget limits. This quality label is a guarantee for investors to find disruptive project proposals from European SMEs with high growth potential.
GlakoLens attended the fifth BIO Startup Turkey accelerator program organized by ReDis Innovation with 12 bio-entrepreneurs. During the program, GlakoLens received one-to-one mentoring and online trainings from experts and leading industry professionals. Following the bio-entrepreneurship camp, GlakoLens pitched in the BIO Startup Demo Day.
By becoming one of the finalists, GlakoLens is going to attend BIO International Convention, the world’s largest global biotech partnering experience.
GlakoLens is selected to participate in the Healthcare Validation Lab Bootcamp, an EIT (European Institute of Innovation and Technology) Health programme provided by YES!Delft, the accelerator of TU Delft.
Participation in this project enables GlakoLens to collect user requirements from a large group of customers (ophthalmologists and patients) making use of proven and credible methodologies. Additionally, the activities conducted in this bootcamp will validate the product-market fit: the customer demand and economic feasibility.
GlakoLens will use the information mined during this accelerator activity to improve the design (or use) of the product within the design control system of GlakoLens and possibly lead to new inventions of innovations.
We’ve been named one of Hello Tomorrow's Deep Tech Pioneers! Selected among more than 5,000 startups from 128 different countries that applied to the Global Challenge. Come and meet us at the Hello Tomorrow Global Summit in Paris on 12th-13th March 2020!
We are proud to announce that our SME Instrument Phase 1 proposal has been awarded this competitive and prestigious grant from the European Community. Our ESR score of 13.91 placed us 89th among the 3275 apllications filed in the last cut-off. This project will enable GlakoLens to conduct an in-depth technical and economic feasibility study culminating into an updated business plan focusing on global commercialization of our innovative technology.
The proprietary technology of GlakoLens will provide ophthalmologists with a powerful diagnostic tool, GlakoSense Platform, in the fight against glaucoma induced blindness. We are foreseeing a future where an early diagnosis of ocular hypertension will prevent deterioration of quality of life due to sight loss and consequent economic and social burden on societies.